Home » Overcoming Bioanalytical Challenges in Anti-Drug Antibody Detection for ADCs

Overcoming Bioanalytical Challenges in Anti-Drug Antibody Detection for ADCs

Created: September 26, 2025

Overcoming Bioanalytical Challenges in Anti-Drug Antibody Detection for ADCs

Discover how expert bioanalytical teams are tackling the complexities of antibody-drug conjugate (ADC) development in our on-demand webinar, “Overcoming Bioanalytical Challenges in Anti-Drug Antibody Detection for ADCs.” Join Martin Roberge, PhD, Director of Development & Innovation at Cerba Research, as he shares a real-world case study and practical strategies to address high rates of pre-existing antibodies, method validation hurdles, and assay sensitivity optimization in ADC clinical trials. Gain actionable insights into adapting ADA assay design to the unique demands of next-generation drug modalities and learn valuable lessons that can inform your own approach to complex biologic drug development.

Fill the form below to watch the webinar for free.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

First name*

Last name*

Email*

Company*

Job function

Phone

Country*

By submitting information on this form, you are agreeing to the terms of our Privacy Policy. You have the right to unsubscribe from email communication at any time.